Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
Company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression
Portfolio comprises three targets, each of which is measurable in plasma and correlates with disease severity
Proceeds will advance programs into cl... Biopharmaceuticals, Venture Capital Mediar Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Venture Capital